188 filings
8-K
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
8-K
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
ADAP
Adaptimmune Therapeutics Plc
16 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
ADAP
Adaptimmune Therapeutics Plc
31 Jan 24
Other Events
5:07pm
8-K
1gxkkvu2uzd5l mg
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
527hijg j6u9of
6 Dec 23
Other Events
7:13am
8-K
1zm45 ewr
14 Nov 23
Other Events
12:00am
8-K
795bca2t4feg066tsynm
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
l738alt
3 Nov 23
Departure of Directors or Certain Officers
4:15pm
8-K
sjggyy9 r1wfyth1uq
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
pe8cuy4hne
31 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:19pm
8-K/A
qfd85i
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
runpgrfv
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
f4alt7x9
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
gny2 kmg17fczin
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
8lajnu1
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
qqlsng
22 May 23
Other Events
6:59am
8-K
oq51y1p5yddtrs5zn2k
16 May 23
Submission of Matters to a Vote of Security Holders
7:35am
8-K
ihxaybg4xvj 0i
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am